A large designer, developer and manufacturer of drug delivery systems is active in R&D, design and manufacturing in all areas of healthcare. The firm is capable of a variety of deal structures, but prefers to enter into joint ventures and strategic partnerships as the firm seeks to be a value-added investor providing their expertise and capabilities in design and manufacturing as well as the resources of a large company while allowing the entrepreneur to drive the development of the technology.
The firm’s expertise lies in drug delivery devices, but has capabilities and is highly interested in all areas of medical technology/devices, biosensors and wearables, B2B or B2C healthcare IT applications including data analytics and cloud computing as well as robotics and AI as it applies to surgery prosthetics, rehabilitation and drug discovery. The firm has a particular interest in the diabetes space and has done work in this area in the past.
The firm is open to working with all entrepreneurs and is open to companies on a global basis. The firm does look for a board seat along with an investment, but strives to not be restrictive in any way and let the management team run the company.
If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.
Founded in 2014, a venture capital firm specializes in life sciences and medical technology, managing both RMB and USD funds with a total size of $600M. The firm is located in Beijing, China, operated by a professional team with diversified and profound industry backgrounds, having made over 40 investments with high growth potential since 2014. For the firm’s RMB fund, the typical allocation size is 30M-50M RMB, and can go up to 200M RMB. For the USD fund, the firm invests $5M USD on average and can go up to $20M USD.
The firm is open to investing in general Bio-medical industries globally, including diagnostics, medical devices, therapeutics and AI in the healthcare service platform. The firm is especially interested in medical imaging, minimally invasive diagnosis specially IVD and treatment, diagnostic reagents and mobile health. The firm prefers diagnostics companies that are at the growth stage but are looking for biotech companies in the seed stage. It’s not interested in small molecules nor antibodies for now.
The firm prefers companies with China Angle, focusing on promising pioneers that operate in healthcare subsegments with lower regulatory risks and introduce global technology into the Chinese market.
If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
It has been over a year since Life Science Nation (LSN) started organizing virtual conferences, which has been met with overwhelming support from the community of investors, service providers, and early-stage companies within life science and healthcare. Thank you to all who have supported LSN throughout the past year!
LSN is pleased to announce the newest, 3-day Digital RESI conference, June 8-10. Check out the agenda below!
Digital RESI June Agenda
Tuesday June 8
Wednesday June 9
Thursday June 10
10:00am
Corporate Venture Capital The Corporate Landscape Morphed & New Opportunities Abound
Angel Investors Explaining the Process of Engagement
Medtech Strategics Large Medical Device Firms Seeking External Innovation
12:00pm
Innovator’s Pitch Session #1
Innovator’s Pitch Session #3
Innovator’s Pitch Session #5
2:00pm
Impact Investors Life Science Investors Looking for More Than Financial Returns
Family Offices How Do Family Offices View Seed & Series A Rounds?
Big Pharma Pipeline Strategy for Preclinical and Early Clinical Assets
3:00pm
Innovator’s Pitch Session #2
Innovator’s Pitch Session #4
Innovator’s Pitch Session #6
Each panel is held live during the conference and will feature active investors and strategic partners as participants sharing their insights and offering helpful tips to fundraising executives.
Digital RESI June will also feature the Innovator’s Pitch Challenge (IPC) – the virtual pitch experience in which participating companies receive a dedicated webpage accessible via the event live agenda, as well as the opportunity to engage in a live Q&A session with investors and strategic partners interested in their products and services. These sessions provide valuable insights and feedback to help companies improve their skills, as well as build connections in a valuable setting.
Life Science Nation (LSN)’s 4D Meets AI partnering conference successfully concluded last Friday, March 19. Over the two-day event, LSN featured seven exceptional startup companies at the intersection of AI and life science through the Innovator’s Pitch Challenge (IPC).
Each company was featured on a dedicated landing page that hosted their pitch video and supplementary materials, and they participated in a live Q&A session with a panel of investor pitch judges. Conference attendees were able to visit these landing pages or join the live Q&A sessions, and they were encouraged to vote for their favorite IPC companies before the end of the conference.
Many thanks to all the IPC companies for their hard work promoting their technologies and to the pitch judges who supported each session with their feedback. Each company was judged on their supporting materials, as well as their live pitch and Q&A. Congratulations to Huma.AI and Thrive Bioscience for winning their sessions!
Huma.ai is a venture-backed healthcare AI company. It’s ML-enabled, questions and answers-driven knowledge automation platform turns domain experts into their own data scientists so that they can make real-time decisions driven by data. According to its customers, Huma.ai has cracked the Holy Grail.
Thrive is commercializing a family of instruments and software that provide previously unavailable data, imaging, analytics, and automation for cell culture, stem cell culture, and tissue culture for use in biomedical research and cell therapeutics. Thrive has recently started selling the first two instruments in the family, the CellAssist and the CellAssist 50. Both collect 1,000’s of images of live cells in culture, analyzes them, provides guidance and builds a significant database. The CellAssist 50 enables researchers to automatically and remotely image 50 plates of cells on an ongoing basis, generating large amounts of data for live cell biology. Sites include Harvard Stem Cell Institute, Center for Genomic Medicine (Massachusetts General Hospital), Stanford Stem Cell Core, University of Texas Medical Branch, as well as large and small pharma/biotech companies.
By Jessica Yang, Senior Research Analyst, Asia Business Development, LSN
Life Science Nation (LSN)’s 2-day Longevity, Health & Innovation (LHI) digital partnering conference took place March 18-19. We are very excited to announce the Top Winners of each Innovator’s Pitch Challenge (IPC) session. As the popularity grows for LHI IPC, we had three sessions featuring Therapeutics, Medical Devices & Diagnostics, and Digital Health companies. Attendees voted for their favorite companies based on materials available on the companies’ dedicated webpages, as well as their live pitch and Q&A.
Thank you to each IPC company for participating and sharing your technology and story with the LHI community. Congratulations to the winners, and thanks to all for voting!
Session 1 (Therapeutics) Tied Winners
APIE-Therapeutics, Inc is a preclinical stage biopharmaceutical company pioneering the endothelium vascular niche repair and regeneration platform. By harnessing activation of the Apelin-APJ receptor, we intend to improve patients’ lives suffering from chronic diseases such as Idiopathic Pulmonary Fibrosis (IPF), KidneyMembranous Glomerulonephritis (MGN) & Chronic Kidney Disease (CKD), Scleroderma (SSc) and others.
Panaceutics Rx uses its patented technologies to enable easy access to affordable personalized medicine and wellness, offering unique combination forms to improve adherence, delivered direct to patients. Our mission is to enable personalized combination products for prevention and chronic therapy, with aids to formulation based on an individual’s digital health profile. Individualized, optimized combinations are enabled to be made on-demand using our robotic platforms and patented processes. Under 503A regulatory rules, Panaceutics automates the compounding of individualized therapies to match physician’s prescriptions. We deliver individualized combination therapies in consumer-friendly forms that promote adherence.
Session 2 (Digital Health) Winner
LifeBio is an age-tech company that captures individuals’ life stories and increases social connectedness— to enhance mental health and to improve Alzheimer’s care.
Session 3 (Medical Devices & Diagnostics) Winner
Eye movements offer a window into brain health. neuroFit licensed a NASA-developed oculometric technology co-invented by one of our founders that delivers eye-movement-based metrics, some well-known from physiology (e.g., latency, acceleration, gain) and other more modern sensorimotor metrics (e.g., direction noise, speed tuning) distilled into a summary metric, nFit. Compared to biomarkers from imaging and EEG, oculometric approaches require only a visual display and a well-designed tracking system to yield noninvasive, low-cost biomarkers that can be scaled on consumer devices.
A life sciences venture capital firm based in USA is focused on early and growth-stage biotech and pharma companies. The group has $300M assets under management and recently closed its third fund. Initial investments typically are in the $3M-$8M range and are usually in the form of equity, but may use convertible notes in select situations. The firm look to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.
The firm is most interested in the biotech/therapeutics space. The firm does not invest in diagnostic or healthcare IT companies. The firm is mostly opportunistic in terms of technology type and indication area; however, the group prioritizes companies with products addressing unmet medical needs and unique mechanisms of action. Bios typically invests in companies ranging from late preclinical to Ph. II clinical trials.
The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A venture capital firm based in Western Europe is looking to make 4-5 investments over the next 6 to 12 months. could lead any investment up to €15M but will also look for syndicate participation in bigger rounds. Allocations are in the form of equity. Allocations are typically made at the venture stage of development but are open to consider Seed through IPO rounds. The firm focuses on companies based in Europe, but also considers companies in Israel and USA.
The firm will look at a broad spectrum of products and services within the life science space. While the firm has traditionally not considered therapeutics, the firm is now open to making investments in this space. The firm is most interested in medical devices and diagnostics including in-vitro diagnostics, and also looks into digital health. They will look at any stage of development within those categories and long as the product or service shows substantial market potential and have proof of concept.
The firm is willing to work with all types of management teams as long as entrepreneurs/founders have a solid knowledge in the industry. A board seat is required for all investments.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Next Phase Newsletter 